{"sourcedb":"DevicePMAs@therightstef","sourceid":"P100034_S000","text":"Approval for the novottf-100a system.  The device is indicated for treatment of adult patients (22 years of age or older) with histologically- confirmed glioblastoma multiforme, following histologically- or radiologically- confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy.  The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for gbm after surgical and radiation options have been exhausted.","project":"consensus_PMA_Age_Indications","denotations":[{"id":"T3","span":{"begin":115,"end":120},"obj":"age_end"},{"id":"T4","span":{"begin":99,"end":104},"obj":"age_start_unit"},{"id":"T5","span":{"begin":96,"end":98},"obj":"age_start"},{"id":"T2","span":{"begin":96,"end":120},"obj":"age_range"},{"id":"T1","span":{"begin":80,"end":85},"obj":"age_category"}]}